On February 13, Bio-Thera announced that the marketing application for Gotenfia® (BAT2506, golimumab injection) had been approved by the European Medicines Agency, with indications including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, and ulcerative colitis.
BAT2506 is a golimumab biosimilar developed by Bio-Thera in accordance with biosimilar guidelines from the National Medical Products Administration, the U.S. Food and Drug Administration, and the European Medicines Agency. The marketing application for BAT2506 has also been accepted by the NMPA, the FDA, and Brazil’s National Health Surveillance Agency, and its commercialization licensing partnerships currently cover 115 countries and regions.
Golimumab is an antibody targeting TNF-alpha. It specifically binds with high affinity to both soluble and transmembrane human TNF-alpha, blocks the binding of TNF-alpha to its receptor TNFR, and thereby inhibits TNF-alpha activity.
Golimumab was originally developed by Johnson & Johnson and recorded sales of USD 2.668 billion in 2025.